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Summary
Background Although international guidelines support the administration of hormone therapies with or without 
targeted therapies in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast 
cancer, upfront use of chemotherapy remains common even in the absence of visceral crisis. Because first-line or 
second-line treatments, or both, based on chemotherapy and on hormone therapy have been scarcely investigated in 
head-to-head randomised controlled trials, we aimed to compare these two different approaches.
Methods We did a systematic review and network meta-analysis with a systematic literature search on PubMed, 
Embase, Cochrane Central Register of Clinical Trials, Web of Science, and online archives of the most relevant 
international oncology conferences. We included all phase 2 and 3 randomised controlled trials investigating 
chemotherapy with or without targeted therapies and hormone therapies with or without targeted therapies as first-
line or second-line treatments, or both, in postmenopausal women with hormone-receptor-positive, HER2-negative 
metastatic breast cancer, published between Jan 1, 2000, and Dec 31, 2017. Additional recently published randomised 
controlled trials relevant to the topic were also subsequently added. No language restrictions were adopted for our 
search. A Bayesian network meta-analysis was done to compare hazard ratios (HRs) for progression-free survival 
(the primary outcome), and to compare odds ratios (ORs) for the proportion of patients achieving an overall response 
(the secondary outcome). All treatments were compared to anastrozole and to palbociclib plus letrozole. This study is 
registered in the Open Science Framework online public database, registration DOI 10.17605/OSF.IO/496VR.
Findings We identified 2689 published results and 140 studies (comprising 50 029 patients) were included in the analysis. 
Palbociclib plus letrozole (HR 0·42; 95% credible interval [CrI] 0·25–0·70), ribociclib plus letrozole (0·43; 0·24–0·77), 
abemaciclib plus anastrozole or letrozole (0·42; 0·23–0·76), palbociclib plus fulvestrant (0·37; 0·23–0·59), ribociclib 
plus fulvestrant (0·48; 0·31–0·74), abemaciclib plus fulvestrant (0·44; 0·28–0·70), everolimus plus exemestane 
(0·42; 0·28–0·67), and, in patients with a PIK3CA mutation, alpelisib plus fulvestrant (0·39; 0·22–0·66), and several 
chemotherapy-based regimens, including anthracycline and taxane-containing regimens, were associated with better 
progression-free survival than was anastrozole alone. No chemotherapy or hormone therapy regimen was significantly 
better than palbociclib plus letrozole for progression-free survival. Paclitaxel plus bevacizumab was the only clinically 
relevant regimen that was significantly better than palbociclib plus letrozole in terms of the proportion of patients 
achieving an overall response (OR 8·95; 95% CrI 1·03–76·92).
Interpretation In the first-line or second-line setting, CDK4/6 inhibitors plus hormone therapies are better than 
standard hormone therapies in terms of progression-free survival. Moreover, no chemotherapy regimen with or 
without targeted therapy is significantly better than CDK4/6 inhibitors plus hormone therapies in terms of 
progression-free survival. Our data support treatment guideline recommendations involving the new combinations 
of hormone therapies plus targeted therapies as first-line or second-line treatments, or in both settings, in women 
with hormone-receptor-positive, HER2-negative metastatic breast cancer.
Funding None.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
The most common subtype of metastatic breast cancer is 
hormone-receptor-positive, HER2-negative breast cancer, 
accoun ting for approximately 65% of all metastatic breast 
tumours.1,2 Despite a favourable prognosis relative to 
other subtypes of metastatic breast cancer, outcomes of 
hormone-receptor-positive, HER2-negative metastatic 
breast cancer remain poor, with a median overall survival 
Articles
www.thelancet.com/oncology   Vol 20   October 2019 1361
of 36 months.2,3 The oestrogen receptor signalling 
pathway is the main driver of cancer cell growth and 
survival in these tumours, so endocrine-based therapies 
are considered the most effective treatments.2 In the past 
decade, randomised controlled trials have led to the 
introduction of several innovative therapeutic strategies 
into clinical practice, consisting of new targeted therapies 
combined with hormone treatments, both in endocrine-
sensitive and endocrine-resistant metastatic breast 
cancer. The most relevant examples of these new 
targeted therapies are the mTOR inhibitor everolimus 
and the CDK4/6 inhibitors palbociclib, ribociclib, and 
abemaciclib, which are used in combination with 
hormone therapies. Pivotal randomised controlled trials 
have proven the efficacy of these combinations as first 
and subsequent lines of treatment for postmenopausal 
patients with hormone-receptor-positive, HER2-negative 
metastatic breast cancer, with substantial improvements 
in patient outcomes.4–10 As a result, according to all 
major international oncology guidelines, a sequence of 
endocrine-based treat ments should be the preferred 
strategy in hormone-receptor-positive, HER2-negative 
metastatic breast cancer, except in instances of life-
threatening visceral disease or visceral crisis.11–14 
Nevertheless, real-world data suggest that upfront use of 
chemotherapy is still common, even in the absence of 
visceral crisis.15–18 This treatment approach might be partly 
due to the paucity of direct comparisons among hormone 
therapies and chemo therapy-based regimens for this 
subtype of metastatic breast cancer.
To provide additional evidence to guide treatment 
choices in postmenopausal patients with hormone-
receptor-positive, HER2-negative metastatic breast 
cancer, we did a comprehensive systematic review and 
network meta-analysis to evaluate the efficacy and activity 
of several hormone therapy and chemotherapy regimens 
that have been investigated in randomised controlled 
trials as first-line or second-line treatments, or both.19
Methods
Search strategy and selection criteria
For this systematic review and network meta-analysis we 
searched the literature on Jan 2, 2018, to identify 
published phase 2 and 3 randomised controlled trials 
evaluating the anti-tumour activity or clinical efficacy, 
or both, of chemotherapy with or without targeted 
therapies and of hormone therapies with or without 
targeted therapies in postmenopausal (physiological or 
induced by gonadotropin-releasing hormone analogues 
or surgery) hormone-receptor-positive, HER2-negative 
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Research in context
Evidence before this study
We did a systematic literature search on Jan 2, 2018, to identify 
published phase 2 and 3 randomised controlled trials 
investigating the antitumour activity or clinical efficacy, or both, 
of chemotherapy with or without targeted therapies and of 
hormone therapies with or without targeted therapies in 
postmenopausal (physiological or induced by 
gonadotropin-releasing hormone analogues or surgery), 
hormone-receptor-positive, HER2-negative, metastatic breast 
cancer, as a first-line or second-line treatment, or both. The 
literature search was restricted to trials published from 
Jan 1, 2000, to Dec 31, 2017. Online electronic databases 
(PubMed, Embase, Cochrane Central Register of Clinical Trials, 
and Web of Science) and relevant international online congress 
proceedings were consulted. Reference lists from the most recent 
international guidelines were also consulted. Cross-references 
from published trials and most updated reviews or meta-analyses 
of therapeutic strategies in hormone-receptor-positive 
metastatic breast cancer were used to identify additional trials. 
There are few randomised controlled trials directly comparing 
hormone therapies with chemotherapies, in combination with or 
without targeted therapies, for first-line or second-line 
treatment, or both, of postmenopausal patients with 
hormone-receptor-positive, HER2-negative metastatic breast 
cancer. To date, network meta-analyses represent the only 
statistical approach to indirectly compare treatments, providing 
that these treatments have been compared to at least one 
common comparator.
Added value of this study
This study is, to our knowledge, the first to compare the efficacy 
and activity of all currently available chemotherapy and hormone 
therapy regimens, in combination with or without targeted 
therapies, including the recently approved CDK4/6 inhibitors 
palbociclib, ribociclib, and abemaciclib, the PI3K inhibitor 
alpelisib, and the mTOR inhibitor everolimus. To our knowledge, 
this study is also the first to directly compare all three CDK4/6 
inhibitors combined with an aromatase inhibitor or fulvestrant 
and to incorporate results of the BOLERO-6 trial. Our results 
show that CDK4/6 inhibitors combined with endocrine agents 
are better than standard endocrine therapy. No chemotherapy 
regimen, with or without targeted agents, had significantly 
higher efficacy than CDK4/6 inhibitors plus hormone therapies. 
Moreover, the combination of CDK4/6 inhibitors plus hormone 
therapies showed a manageable toxicity profile, of intermediate 
severity between that of hormone therapies and that of 
chemotherapy with or without targeted therapies. There were no 
significant differences in progression-free survival among the 
three CDK4/6 inhibitors.
Implications of all the available evidence
Overall, our results support treatment algorithms recommended 
by the official oncology guidelines for first-line or second-line 
treatment, or both, of postmenopausal patients with 
hormone-receptor-positive, HER2-negative metastatic breast 
cancer without visceral crisis, with the new combinations of 
endocrine therapies and targeted agents.
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meta static breast cancer, as first-line or second-line 
treatments, or both. The literature search was restricted 
to trials published from Jan 1, 2000, to Dec 31, 2017. 
Additional recently published randomised controlled 
trials relevant to the topic were added after their 
publication: MONALEESA 3 in August, 2018, when the 
main article was published; BOLERO-6 in June, 2018, 
when the main article was published; and SOLAR1 in 
October, 2018, when it was presented at the European 
Society of Medical Oncology (ESMO) meeting (appendix 
pp 3–18). Randomised controlled trials exclusively 
enrolling premenopausal patients and those with HER2-
positive or triple-negative breast cancer were excluded 
from the analysis. The recommendations of the Cochrane 
Collaboration were followed to identify all relevant 
randomised controlled trials.20 The full list of search 
terms is provided in the appendix (p 1); we used a 
combination of disease characteristics, study design, 
treatment setting, and strategies or drugs as search 
terms. We searched PubMed, Embase, Cochrane Central 
Register of Clinical Trials, and Web of Science, as well as 
American Society of Clinical Oncology (ASCO) and 
ESMO annual meetings and San Antonio Breast Cancer 
Symposiums (SABCS) online archives. Some records 
were also retrieved via cross-references from published 
trials, the main international oncology guide lines, and 
most updated reviews or meta-analyses of therapeutic 
strategies in hormone-receptor-positive, HER2-negative 
metastatic breast cancer.11–14,21–24 Phase 2 or 3 randomised 
controlled trials published in the form of full papers, or 
as abstracts if full papers were not available, were 
included in the analysis. No language restrictions were 
adopted for our search. Two reviewers (FS and MG) 
independently assessed whether each selected random-
ised controlled trial met the predeter mined criteria, and a 
third reviewer (DG) was consulted in case of 
disagreement. Additional details about the search 
strategy are provided in the appendix (p 1). The full 
reference list is reported in the appendix (pp 3–18).
Data analysis
Details about study design, patient characteristics, 
interventions, and previous treatments were extracted 
from each paper. When duplicate publications were 
identified, only the most recent and complete reports 
of randomised controlled trials were included. Hazard 
ratios (HR) and associated 95% CIs were extracted for 
progression-free survival and time to progression, when 
reported. Odds ratios (ORs) for the proportion of patients 
achieving an overall response, and associated 95% CIs, 
were also retrieved. These data had to be publicly 
available or computable from the included studies.
The primary outcomes were progression-free survival 
(defined as the time from randomisation to either death 
or disease progression, whichever occurred first) and 
time to progression (defined as the interval from random-
isation to tumour progression). If both endpoints were 
reported in a randomised controlled trial, progression-
free survival was selected for inclusion in the meta-
analysis.25,26 The proportion of patients achieving 
an overall response, defined according to Response 
Evaluation Criteria in Solid Tumors (RECIST), was 
selected as a secondary outcome.27 We also did an 
exploratory analysis reporting the proportions of patients 
with grade 3–5 adverse events, according to Common 
Terminology Criteria for Adverse Events, version 4.28
Because of the heterogeneity of the studies included in 
the systematic review, a Bayesian random-effects network 
meta-analysis framework was used for each outcome, 
and results of the network meta-analysis are reported as 
HRs or ORs with 95% credible intervals (95% CrIs).19 The 
parameters of the different models were estimated by 
use of a Markov Chain Monte Carlo method as imple-
mented in the WinBUGS software package.29 For further 
verification, all analyses were also done with a fixed-
effects approach. As expected, the random-effects model 
provided a better fit to the data than the fixed-effects 
model. We assessed the risk of bias for each trial using 
the criteria outlined in the Cochrane Handbook for 
Systematic Reviews of Interventions.20 All analyses were 
done with WinBUGS (version 1.4.3).29
The internal validity of eligible studies was assessed 
according to the Cochrane Collaboration’s Risk of Bias 
tool in Review Manager (version 5.3). Further details on 
the methods used are provided in the appendix (p 2).
The project is registered in the Open Science 
Framework (OSF) online public database, registration 
DOI 10.17605/OSF.IO/496VR.
Role of the funding source
There was no funding source for this study. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Overall, 2689 records were identified. 140 studies were 
selected as they met all the inclusion criteria and were 
included in network meta-analyses (figure 1). A study by 
Dixon and colleagues was included in the meta-analysis 
even though the study was published in 1992, because it is 
the only study comparing hormone therapies with 
chemotherapy, aside from the BOLERO-6 trial, which 
was published after the initial search was done 
(appendix pp 3, 18). Although randomised controlled 
trials specifically designed for triple-negative breast cancer 
were excluded from the analysis, as previously stated, 
several randomised controlled trials testing chemo-
therapy-containing regimens also included patients with 
triple-negative breast cancer. Moreover, older randomised 
controlled trials (published approximately before 2006) of 
hormone therapies enrolled patients with unknown 
hormone receptor status. Three (2%) of 140 trials were 
single-centre studies, 130 (93%) were multicentre trials, 
See Online for appendix
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and for the remaining seven (5%) trials the number of 
involved centres was not reported. A detailed description 
of all the studies included in the network meta-analysis, 
together with patient characteristics, is provided in the 
appendix (pp 19–40).
Among the 140 selected randomised controlled trials, 
114 (81%) were included in a network created to analyse 
HRs for progression-free survival and time to progression 
(figure 2), and 135 (96%) were included in a network 
created to analyse ORs for the proportion of patients 
achieving an overall response (figure 3; full reference list 
in appendix, pp 3–18).
Overall, 50 029 patients were included in our network 
meta-analysis. Patient age ranged from 45·6 years to 
72·6 years (median 58·0 years; IQR 55·0–63·0) and 
follow-up ranged from 4·2 months to 60·0 months 
(median 20·0 months; 14·9–29·1). For 47 (34%) of 
140 trials, information about previous adjuvant or neo-
adjuvant systemic therapies was not reported. 91 (65%) 
randomised controlled trials were exclusively of first-
line treatments, 33 (24%) included both first-line and 
second-line (or further-line) treatments, and 16 (11%) 
comprised at least second-line treatments. For patients 
enrolled in trials of hormone therapies, visceral involve-
ment ranged between 9·0% and 87·0%, with a median of 
53·0% (IQR 47·5–59·0). Visceral involvement for patients 
enrolled in trials of chemotherapies ranged between 9·0% 
and 91·3%, with a median of 72·6% (IQR 63·0–78·8).
All treatments were compared to anastrozole because it 
was the most common comparator present in the 
randomised controlled trials included in the network 
meta-analysis. All treatments were also compared to the 
combination of palbociclib plus letrozole, since this 
was the first combination of a CDK4/6 inhibitor plus 
hormone therapy approved for clinical practice, and 
remains the first-line standard of care, along with other 
CDK4/6 inhibitor plus hormone therapy combinations.
23 treatments were significantly better than anastrozole 
with regard to the primary endpoints of progression-free 
survival and time to progression, including the new 
first-line standard treatments palbociclib plus letrozole 
(HR 0·42; 95% CrI 0·25–0·70), ribociclib plus letrozole 
(0·43; 0·24–0·77), and abemaciclib plus anastrozole or 
letrozole (0·42; 0·23–0·76), and the second-line treat-
ments palbociclib plus fulvestrant (0·37; 0·23–0·59), 
ribociclib plus fulvestrant (0·48; 0·31–0·74), abemaciclib 
plus fulvestrant (0·44; 0·28–0·70), everolimus plus 
exemestane (0·42; 0·28–0·67), and, in patients with a 
PIK3CA mutation, alpelisib plus fulvestrant (0·39; 
0·22–0·66; appendix pp 57–58). Among regimens 
comprising chemotherapy with or without targeted 
therapies, several regimens were better than anastrozole, 
including fluorouracil plus epirubicin plus cyclo-
phosphamide (HR 0·47; 95% CrI 0·26–0·93), paclitaxel 
plus bevacizumab (0·39; 0·18–0·88), capecitabine (0·41; 
0·24–0·76), and eribulin (0·45; 0·23–0·89). No treatment 
was significantly better than palbociclib plus letrozole 
(appendix pp 59–60). However, palbociclib plus 
letrozole was significantly better than fulvestrant plus 
anastrozole (HR 0·47; 95% CrI 0·27–0·83), fulvestrant 
standard dose (0·52; 0·30–0·91), anastrozole (0·42; 
0·25–0·70), letrozole (0·55; 0·40–0·74), exemestane 
(0·43; 0·25–0·75), and tamoxifen (0·38; 0·24–0·61).
Consistent findings were observed when all treatments 
were compared with regimens based on CDK4/6 inhibitors 
(data not shown). We found no significant differences 
in progression-free survival among the three CDK4/6 
inhibitors in combination with an aromatase inhibitor: 
palbociclib plus letrozole versus ribociclib plus letrozole 
(HR 0·98; 95% CrI 0·58–1·66), palbociclib plus letrozole 
versus abemaciclib plus anastrozole or letrozole (1·01; 
0·59–1·70), and abemaciclib plus anastrozole or letrozole 
versus ribociclib plus letrozole (0·97; 0·53–1·78). More-
over, we found no significant differences among the 
three CDK4/6 inhibitors in combination with fulvestrant: 
palbociclib plus fulvestrant versus abemaciclib plus 
fulvestrant (HR 0·83; 95% CrI 0·47–1·46), palbociclib plus 
fulvestrant versus ribociclib plus fulvestrant (0·77; 
2631 records identified and screened for retrieval on PubMed,
 Embase, Web of Science, and Cochrane Central Registry
 of Controlled Trials
2689 records screened
151 eligible articles
140 articles included in the final network meta-analysis
58 additional records identified through other
 sources
 12 from ESMO, ASCO, and SABCS online
 archives 
 46 cross-references
2538 records excluded (phase 1 trials, 
 meta-analyses and reviews, trials for 
 triple-negative breast cancer or 
 HER2-positive breast cancer, 
 single-arm-studies, adjuvant or neoadjuvant 
 trials, non-randomised trials, study protocols,
 observational studies, preclinical studies,
 translational studies, duplicate studies, 
 quality-of-life results or trials, other topics
 (other cancers), pharmacoeconomic studies,
 and absence of required data
14 other articles excluded
 11 absence of required data
 3 no treatment connection in the network
3 late-published articles included after database 
 searching
Figure 1: Study selection
ASCO=American Society of Clinical Oncology. ESMO=European Society of Medical Oncology. HR=hazard ratio. 
OR=odds ratio. SABCS=San Antonio Breast Cancer Symposiums.
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0·44–1·35), and abemaciclib plus fulvestrant versus 
ribociclib plus fulvestrant (0·93; 0·54–1·61).
For the secondary endpoint of the proportion of 
patients achieving an overall response, 27 therapies were 
shown to be significantly better than anastrozole 
(appendix pp 61–62). Among regimens comprising 
hormone therapies with or without targeted therapies, 
the most clinically relevant were everolimus plus 
exemestane (OR 4·50; 95% CrI 1·35–15·55) and 
abemaciclib plus fulvestrant (3·60; 1·22–10.77); 
palbociclib plus letrozole (1·85; 0·59–5·69), ribociclib 
plus letrozole (2·34; 0·65–8·48), abemaciclib plus 
anastrozole or letrozole (2·28; 0·62–8·29), palbociclib 
plus fulvestrant (2·61; 0·80–8·66), and ribociclib plus 
fulvestrant (1·81; 0·61–5·38) were not significantly better 
than anastrozole. Several chemotherapy regimens with 
or without targeted therapies were better than 
anastrozole, including paclitaxel plus bevacizumab (OR 
16·48; 95% CrI 2·30–119·82), paclitaxel once weekly 
(15·0; 1·93–116·16), and docetaxel every 3 weeks plus 
epirubicin (7·64; 1·12–48·89). When compared with 
palbociclib plus letrozole, no treatment resulted in a 
significantly higher proportion of patients achieving an 
overall response, except for paclitaxel once weekly plus 
bevacizumab (OR 8·95; 95% CrI 1·03–76·92; appendix 
pp 63–64). However, none of the other CDK4/6 inhibitor 
plus hormone therapy com binations was significantly 
different to any of the clinically approved chemotherapy-
based regimens in terms of overall response (data not 
shown). We found no significant difference in the 
proportion of patients achieving an overall response with 
palbociclib plus letrozole versus ribociclib plus letrozole 
(OR 0·79; 95% CrI 0·25–2·53), with palbociclib plus 
letrozole versus abemaciclib plus anastrozole or letrozole 
(0·81; 0·25–2·65), or with ribociclib plus letrozole 
versus abemaciclib plus anastrozole or letrozole (1·03; 
0·27–3·91). Moreover, we observed no significant 
difference with palbociclib plus fulvestrant versus 
abemaciclib plus fulvestrant (OR 0·72; 95% CrI 
0·18–2·98), with palbociclib plus fulvestrant versus 
ribociclib plus fulvestrant (1·44; 0·36–5·90), or with 
abemaciclib plus fulvestrant versus ribociclib plus 
fulvestrant (2·00; 0·53–7·52).
The extent of heterogeneity between studies as 
measured by the random-effects model was assessed by 
inspecting the estimate of the corresponding SD. For the 
analysis of the log-HR, the average SD was 0·15 (95% CrI 
0·06–0·26); for the analysis of the log-OR, the average 
SD was 0·43 (0·30–0·60).
Adverse events were reported differently in the 
included studies, so a systematic assessment of safety 
was not possible. However, we did an exploratory analysis 
of the proportions of patients with grade 3–5 adverse 
events.28 We only considered grade 3–5 adverse events 
that were reported in 2% or more patients for each study.
The main adverse events, subdivided according to 
treatment categories, are reported in the appendix 
(pp 41–56). The proportions of adverse events are 
reported as ranges according to the values reported 
in different randomised controlled trials. Single-agent 
chemo therapy was associated with fewer adverse events 
than combination chemotherapy (appendix pp 41–52). 
The most frequent drug-specific adverse events were 
alopecia, most frequently observed with doxorubicin, 
docetaxel, vinorelbine, paclitaxel, and gemcitabine; 
stomatitis, most frequently associated with doxorubicin; 
febrile neutropenia, most frequently associated with 
docetaxel; hand-foot syndrome, mostly associated with 
capecitabine; and motor and sensory neurological 
disorders, mostly associated with taxanes. Combination 
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chemotherapy was associated with higher frequencies of 
haematological and biochemical adverse events than 
single-agent chemotherapy (appendix pp 41–52). How-
ever, grade 3–5 neutropenia and leuco penia were also 
frequent with single-agent chemotherapy.
The most frequent grade 3–5 adverse events observed 
with hormone therapies were increased aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) 
concentrations, mostly with tamoxifen and exemestane; 
hyperglycaemia, mostly with anastrozole; pain (general), 
mostly with tamoxifen and exemestane; bone pain, 
mostly with tamoxifen and anastrozole; arthralgia, mostly 
with letrozole and exemestane; asthenia, mostly with 
exemestane and anastrozole; dyspnoea and con stipation, 
mostly with anastrozole; anaemia, mostly with tamoxifen 
and exemestane; and hypoalbuminaemia, only with 
anastrozole (appendix pp 53–54). Hormone therapy plus 
targeted therapy combinations were asso ciated with 
diarrhoea, mostly observed with abemaciclib plus 
anastrozole, abemaciclib plus letrozole, abemaciclib plus 
fulvestrant, and alpelisib plus fulvestrant; rash and 
fatigue, mostly observed with alpelisib plus fulvestrant; 
stomatitis and pneumonia, mostly observed with 
everolimus plus exemestane; and high frequencies of 
neutropenia and leucopenia were observed with the 
combinations of ribociclib and palbociclib plus letrozole 
or fulvestrant (appendix pp 55–56). Grade 3–5 increases 
in AST and ALT concentrations were observed with 
ribociclib plus letrozole, abemaciclib plus fulvestrant, 
palbociclib plus fulvestrant, and everolimus plus 
exemestane. Additionally, hyper glycaemia was reported 
with alpelisib plus fulvestrant.
A detailed risk of bias evaluation is reported in the 
appendix (pp 64, 65).
Discussion
The findings of this large network meta-analysis confirm 
that the combination of CDK4/6 inhibitors plus hormone 
therapies is better than standard hormone therapies as 
first-line or second-line treatments for postmenopausal 
patients with hormone-receptor-positive, HER2-negative 
metastatic breast cancer. In terms of progression-free 
survival or time to progression, no standard treatment 
schedule of chemotherapy with or without targeted 
therapy was significantly better than CDK4/6 inhibitors 
plus hormone therapies, which, in turn, showed a 
favourable and manageable toxicity profile. No significant 
differences in efficacy and overall activity were observed 
among the three CDK4/6 inhibitors.
In the past decade, several practice-changing ran-
domised controlled trials have shown the efficacy of 
innovative therapeutic strategies as first-line or second-
line treatments, or both, for patients with hormone-
receptor-positive, HER2-negative metastatic breast cancer, 
leading to substantial improvements in patient outcomes. 
The efficacy of hormone therapies in particular has been 
potentiated by combining them with new targeted 
therapies, such as the CDK4/6 inhibitors or mTOR and 
PI3K inhibitors. Median progression-free survival has 
almost doubled and the proportion of patients achieving 
an overall response significantly improved in all pivotal 
trials of hormone therapies combined with CDK4/6 
inhibitors, mTOR inhibitors, and PI3K inhibitors, com-
pared with standard hormone therapies alone.4–10,30 Results 
of these trials have sub stantially changed treatment 
algorithms, further supporting the recommendation of 
oncology guidelines to adopt a sequence of all the 
available endocrine-based treatments and delay chemo-
therapy until occurrence of certain forms of endocrine 
resistance or clinical evidence of visceral crisis.11–14 
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Nevertheless, chemotherapy-based regimens are still 
widely used as upfront therapy, sometimes without strict 
clinical justification.15–18 To date, few data are available 
from randomised controlled trials directly comparing 
hormone therapies to chemotherapy-based treatment 
regimens in this disease subset. Indeed, in the past three 
decades, only two randomised controlled trials addressing 
this issue have been published (appendix pp 3, 18).31,32 
Besides those two trials, only one large retrospective 
analysis was done of patients with hormone-receptor-
positive, HER2-negative metastatic breast cancer who 
were sensitive to aroma tase inhibitors, which compared 
front-line hormone therapies to induction chemotherapy.33 
Moreover, the new combinations of hormone therapies 
plus targeted therapies have not been directly compared 
head to head in randomised controlled trials (ie, 
palbociclib vs ribociclib vs abemaciclib) and new trials are 
unlikely to be designed to address this question. This 
research gap leaves some degree of uncertainty about the 
optimal treatment algorithm in patients with hormone-
receptor-positive, HER2-negative meta static breast cancer. 
In this context, an inclusive and methodologically solid 
network meta-analysis could provide indirect evidence 
supporting physicians’ treatment choice.
In terms of progression-free survival or time to 
progression, our results show that hormone therapies 
plus targeted therapies as first-line or second-line 
treatments, or in both settings, remain the best treatment 
choice, because chemotherapy was not shown to be better 
than endocrine therapy with targeted agents even when 
highly active chemotherapy regimens (ie, taxane-based or 
anthracycline-based regimens, or regimens containing 
both drugs) were used as a comparator. Treatment 
strategies involving hormone therapies plus targeted 
therapies, including inhibitors of tumour metabolism 
such as alpelisib or everolimus plus hormone therapies 
and the three CDK4/6 inhibitors plus hormone therapies, 
were all significantly better than single-agent hormone 
therapies with anastrozole. Several chemotherapy regi-
mens, including some based on taxanes or anthra-
cyclines, or both, did not show significantly better efficacy 
in comparison with hormone therapies alone (eg, 
anastrozole). This observation is valuable, especially for 
countries where CDK4/6 inhibitors, and targeted 
therapies in general, are not available yet.
With regard to the proportion of patients achieving an 
overall response, by comparison with contemporary 
single-agent chemotherapy and combination chemo-
therapy regimens with or without targeted therapies, 
palbociclib plus letrozole was significantly less active 
than bevacizumab-containing treatments only, including 
paclitaxel plus bevacizumab, although paclitaxel plus 
bevacizumab failed to show greater activity than the 
other combinations of CDK4/6 inhibitors plus hormone 
therapies. However, to correctly interpret these data, it is 
important to consider that studies of chemotherapy plus 
bevacizumab also enrolled patients with triple-negative 
disease, higher proportions of whom might achieve 
overall responses with these regimens than would be 
typically observed in patients with hormone-receptor-
positive, HER2-negative breast cancer. Among the 
hormone-receptor-positive, HER2-negative subgroups in 
the TURANDOT and the CALGB 40502 trials, 35% to 
46% of patients achieved an overall response with 
paclitaxel plus bevacizumab.34,35 Notably, despite all the 
limitations of indirect comparisons, the proportion of 
patients achieving an overall response was not higher 
than that observed in trials of CDK4/6 inhibitors as first-
line treatments.
None of the three CDK4/6 inhibitors, either combined 
with an aromatase inhibitor or fulvestrant, appeared to 
be better than the others in terms of both progression-
free survival and the proportion of patients achieving an 
overall response; this observation provides new evidence 
for another crucial point of uncertainty regarding 
treatment choices in the first-line and second-line setting 
for hormone-receptor-positive, HER2-negative metastatic 
breast cancer.
The exploratory analysis of safety showed that the toxicity 
of combinations comprising CDK4/6 inhibitors plus 
hormone therapies was of intermediate severity between 
that of standard hormone therapies and that of chemo-
therapy with or without targeted therapies. Moreover, 
although haematological adverse events were frequent 
with regimens containing CDK4/6 inhibitors, they were 
not accompanied by consistent rates of febrile neutro-
penia.4–10 Some distinctive grade 3–5 adverse events 
differentiate the combination of abemaciclib (mostly 
diarrhoea) from palbociclib-containing and ribociclib-
containing therapies (mostly haematological and hepatic 
toxicity), and from everolimus plus exemestane (mostly 
stomatitis and pneumonia) or alpelisib plus fulvestrant 
(mostly hyperglycaemia and rash). Side-effects are reported 
differently in large international trials. Over-reporting or 
under-reporting can occur, depending on the location and 
setting of the study or as a result of different race-
dependent safety profiles. Head-to-head comparisons are 
the best way to understand differences in safety profiles. 
The effect of different treatments on quality of life is even 
more complex. Fortunately, quality-of-life assessments are 
now systematically included as an important secondary 
endpoint in trials investigating different treatments in 
metastatic breast cancer. Despite these challenges, safety 
profiles, together with efficacy data and evidence of the 
effect of treatments on quality of life,36,37 support the use of 
hormone therapies plus targeted therapies and support 
delaying administration of chemotherapy. However, 
financial costs remain a major issue. Access to new drugs, 
as well as the direct and indirect costs of treatment, vary 
substantially from one country to another. High-quality 
pharmacoeconomic studies are therefore needed to 
integrate costs into treatment algorithms.
Our network meta-analysis has some limitations. First, 
we acknowledge the heterogeneity among the included 
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studies, treatments, and patient populations, as a result 
of the long publication period considered (18 years), as 
also shown by the estimation of the random effects. 
Diagnostic advances could have produced a stage 
migration (ie, improvements in diagnosis of metastatic 
disease over time) that might have influenced disease 
features and patient prognosis. Advances in histo-
pathology, including changes to techniques for assessing 
hormone receptor status, might also have provided better 
selection of patients deriving benefit from hormone 
therapies.
Large phase 3 trials investigating CDK4/6 inhibitors 
have shown consistent benefit of these agents combined 
with hormone therapies when compared with hormone 
therapies alone, independently of clinical subgroups. 
However, the benefits of chemotherapy are possibly 
more pronounced in more aggressive and less endocrine-
sensitive tumours than in slowly growing, highly 
endocrine-sensitive tumours. Our network meta-analysis 
did not allow analysis of specific subgroups to detect a 
differential effect according to subpopulations. It would 
be interesting to do this subgroup analysis in the large 
phase 3 PEARL trial (NCT02028507), which directly 
compares palbociclib plus exemestane or plus fulvestrant 
versus capecitabine. No information is available about 
the efficacy of CDK4/6 inhibitors in patients presenting 
with a visceral crisis, as these patients were excluded 
from these trials.
Additionally, we were unable to do separate analyses 
for first-line, second-line, and subsequent lines of 
therapy, since only a few studies included in the network 
meta-analysis (mostly recent trials) focused on one 
specific line of therapy (ie, randomised controlled 
trials of purely first-line or second-line treatments). 
Additionally, although randomised controlled trials 
specifically designed for patients with triple-negative 
breast cancer had been excluded, several studies 
investigating chemotherapy regimens enrolled also 
patients with triple-negative breast cancer, as previously 
mentioned. Other important endpoints cannot be 
analysed accurately by our network meta-analysis. In 
particular, whether a specific sequence affects overall 
survival remains a major debate. Unfortunately, to our 
knowledge, few trials have been designed to answer 
this clinically relevant question. The SONIA trial 
(NCT03425838) will investigate the optimal position of 
CDK4/6 inhibitors in the first-line or second-line setting 
for patients receiving a non-steroidal aromatase inhibitor 
in the first-line setting, and fulvestrant in the second-line 
setting for hormone-receptor-positive, HER2-negative 
metastatic breast cancer.
We did not report publication bias because the 
approaches developed to assess this type of bias in 
network meta-analyses have limitations and their 
effectiveness is often debated. Moreover, verifying the 
presence of publication bias in network meta-analyses is 
notoriously challenging, as funnel plots within this 
context need a special adjustment because the studies 
compare different pairs of interventions.38 However, our 
analysis includes most of the available literature on 
the topic, which might mitigate the effect of publication 
bias. Finally, all network meta-analyses share the 
same limitations of standard pairwise meta-analyses.39,40 
Moreover, these meta-analyses are based on an additional 
set of assumptions, the foremost being consistency 
between direct and indirect evidence, on which a lot of 
research is still ongoing.41
Despite these limitations, we believe the results of 
this large network meta-analysis are timely, clinically 
meaningful, and methodologically reliable. The internal 
validity of the eligible studies was successfully assessed 
with the most appropriate risk of bias analysis.20 Our 
data are consistent with previously published net work 
meta-analyses, although, to our knowledge, this analysis 
comprises the largest number of randomised con-
trolled trials ever reported in hormone-receptor-positive, 
HER2-negative metastatic breast cancer and is the first 
comprehensive network meta-analysis to provide an 
indirect comparison of all CDK4/6 inhibitors plus 
aromatase inhibitors or fulvestrant and chemotherapy-
based regimens.21–24 Moreover, this network meta-
analysis is the first to include the BOLERO-6 trial, 
which, despite its small sample size, represents the 
only contemporary study directly comparing a hor-
mone therapy plus targeted therapy (everolimus plus 
exemestane) versus chemo therapy (capecitabine), a 
regimen that is currently used in clinical practice 
(appendix p 18).32 Results from the ongoing phase 3 
PEARL trial are likely to provide additional evidence on 
this topic. According to the results of our network meta-
analysis, if patients with hormone-receptor-positive, 
HER2-negative metastatic breast cancer are treated with 
CDK4/6 inhibitors in the first-line setting, they might 
still benefit from hormone therapies such as the 
combination of everolimus plus exemestane, or alpelisib 
plus fulvestrant in patients with a PIK3CA mutations, 
and thus delay chemotherapy.
In conclusion, our results corroborate the treatment 
algorithms recommended by the official oncology 
guidelines, supporting the use of new combinations of 
hormone therapies plus targeted therapies in the first-
line or second-line setting in patients with hormone-
receptor-positive, HER2-negative metastatic breast 
cancer without visceral crisis.
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